First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
TCTMD,
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson
– Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study…
"The delivery of 90 watts of RF power in a short, four-second ablation session is a significant advancement in the treatment of…
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson
SOURCE Biosense Webster, Inc. IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is…
SOURCE Biosense Webster, Inc. IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is…
SOURCE Biosense Webster, Inc. IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is…
SOURCE Biosense Webster, Inc. IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is…
SOURCE Biosense Webster, Inc. IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is…
IRVINE, Calif. "The delivery of 90 watts of RF power in a short, four-second ablation session is a significant advancement in…
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ -- Johnson